Viracept (nelfinavir)
- Region
- 🇪🇺 EU
- Active substance
- nelfinavir
- Company
- Roche Registration Ltd.
- Status
- Withdrawn
- Therapeutic area
- HIV Infections
- EU approval
- Thu 22 Jan 1998
- Application
- EMEA/H/C/000164
- ATC
- J05AE04
- Official record
- www.ema.europa.eu
Indication
Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older. In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.
Regulatory milestones
No milestones recorded in the last year.
Follow Viracept
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.